BIXT (Bioxytran) EBITDA Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Bioxytran EBITDA Margin %?

Bioxytran BIXT +11.48% EBITDA Margin % is 0.00% as of Mar. 2026. The stock has 3 warning signs investors should review. Among 939 Biotechnology companies, Bioxytran ranks worse than 106496.17% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bioxytran's EBITDA for the three months ended in Mar. 2026 was $-2.01 Mil. Bioxytran's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Bioxytran's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Bioxytran  (OTCPK:BIXT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Bioxytran EBITDA Margin % Related Terms

Bioxytran EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Bioxytran's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioxytran EBITDA Margin % Chart

Bioxytran Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bioxytran Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BIXT vs SPRC, ACUT, DCOY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Bioxytran's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioxytran EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioxytran's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Bioxytran's EBITDA Margin % falls into.


Bioxytran EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Bioxytran's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-1.925/0
= %

Bioxytran's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-2.006/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Bioxytran (BIXT) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioxytran and its competitors. According to the industry distribution chart, Bioxytran ranks #999999 out of 939 companies in the Biotechnology industry.
Is Bioxytran's EBITDA Margin % too high?
Bioxytran's current EBITDA Margin % is 0.00%. Based on the distribution chart, Bioxytran ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Bioxytran's EBITDA Margin % compare to SPRC and ACUT?
According to the Biotechnology industry distribution chart, Bioxytran ranks #999999 out of 939 companies for EBITDA Margin %. This places Bioxytran in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioxytran and its competitors. Bioxytran's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioxytran stock overvalued right now?
Bioxytran (BIXT) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bioxytran (BIXT), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioxytran Business Description

Address 75 2nd Avenue, Suite 605, Needham, MA, USA, 02494
Bioxytran Inc is a clinical stage pharmaceutical company developing platform technologies in the fields of Glycovirology, Hypoxia and Degenerative Diseases to eliminate viruses and prolong lifespan using carbohydrate drug design. Bioxytran uses Galectin inhibitors to combat the virus, SARS-CoV-2. Glycovirology is a novel glycan-based platform technology. The concept involves using sugar-based drugs to block viruses. The company is developing an inventive platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention.